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ABSTRACT
Background: The 2006 Global Initiative for Asthma (GINA 2006) guidelines emphasize the importance of
evaluating the control rather than the severity of asthma. The Asthma Control Test (ACT) is well known to be an
excellent tool for evaluating asthma control in the clinical setting. This study aimed to evaluate the ACT, Japa-
nese version (ACT-J) as a predictor of asthma control as defined by the GINA 2006 guidelines in actual clinical
practice.
Methods: A cross-sectional analysis comparing the ACT-J score and GINA classification of asthma control
among 419 patients of primary care physicians and specialists was performed using the data from a 2010
questionnaire-based survey conducted by the Niigata Asthma Treatment Study Group.
Results: The optimal cut-off point of the ACT-J score for predicting GINA-defined asthma control was 23, with
ACT-J scores of23 and22 predicting controlled and uncontrolled asthma with area under the receiver oper-
ating characteristics curve values of 0.76 [95% confidence interval (CI): 0.72-0.81] and 0.93 [95% CI: 0.90-
0.97], respectively.
Conclusions: ACT scores of 23 and 22 are useful for identifying patients with controlled and uncontrolled
asthma, respectively, as defined by GINA 2006, and the latter is more strongly predictive than the former. The
reason for the higher cut-off point of the ACT-J relative to other versions of the ACT is unclear and warrants fur-
ther investigation.
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ABBREVIATIONS
ACT, Asthma Control Test; ACT-J, Japanese version of the Asthma Control Test; AUC, area under the curve;
CI, confidence interval; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; IQR, interquartile range;
LABA, long-acting beta agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; OSRT, oral
sustained-release theophylline; PEFM, peak-flow meter; ROC, receiver operating characteristic; %PEF, the
PEFM value as a percentage of the predicted PEFM value.
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INTRODUCTION
The Global Initiative for Asthma (GINA) and other
asthma management guidelines based on the GINA
guidelines have promoted remarkable improvement
in asthma management.1-3 These guidelines, includ-
ing the 2006 GINA guidelines (GINA 2006), require
the clinician to achieve current control of asthma and
decrease the risk for future asthma exacerbation
rather than merely evaluate the severity of asthma.4,5
Therefore, it is extremely important to evaluate
asthma control in each patient in order to use these
guidelines appropriately, and the GINA guidelines
provide the criteria for such evaluations.
As asthma is one of the most common diseases,6-8
asthma management requires not only specialists but
also general physicians, with the role of general phy-
sicians being extremely important. Studies of actual
clinical care have indicated that lung function tests,
including the forced expiratory volume in 1 second at
peak expiratory flow and peak flow, both of which are
required under most circumstances for proper evalu-
ation of asthma control under the guidelines, are only
poorly used.3,9-11 Therefore, in actual clinical care, it
is more realistic to use criteria other than lung func-
tion parameters, instead of the GINA criteria, to
evaluate asthma control.
The Asthma Control Test (ACT), which was devel-
oped in 2004, is a simple, self-administrated, and rap-
idly completed assessment tool comprising 5 ques-
tions.12 This tool is recognized as better for achieving
asthma control13-15 despite requiring no lung function
tests. Several studies have shown that the ACT can
be an excellent predictor of asthma control as defined
by the GINA guidelines.16-19 Although the Japanese
version of the ACT (ACT-J) was introduced in 2006,
no similar analysis of the ACT-J has yet been per-
formed.
In 1998, the Niigata Asthma Treatment Study
Group began conducting annual or biennial surveys
to investigate various asthma control and manage-
ment problems.20-28 We analyzed data from the
questionnaire-based 2008 survey and reported that
the ACT-J is both reliable and valid.29 In order to al-
low evaluation of the ACT-J as a predictor of GINA
2006-defined asthma control in actual clinical prac-
tice, the questions in the 2010 survey concerning the
criteria for asthma control were based on the GINA
2006 guidelines. Therefore, the present study used
data from the 2010 questionnaire-based cross-
sectional survey to compare the ACT-J score and
GINA classification of asthma control and analyze the
usefulness of the ACT-J as a predictor of GINA 2006-
defined asthma control.
METHODS
Participation in this study was open to all medical in-
stitutions in Niigata Prefecture, Japan, that intended
to join the Niigata Asthma Treatment Study Group.
The study was performed with the approval of the
Ethics Committee at the School of Medicine of Nii-
gata University (approval #1090) in Niigata Prefec-
ture, Japan, in accordance with the Ethical Principles
for Medical Research Involving Human Subjects
(Declaration of Helsinki). Written informed consent
to participate was obtained from all patients. The
questionnaire was written in Japanese. The question-
naire survey was administered between September
and October 2010. The subjects comprised patients
aged 16 or more years with bronchial asthma who
regularly visited the participating institutions for
asthma management (typically once or twice per
month). The recruited patients were asked to com-
plete the questionnaire without assistance and were
thus expected to understand the technical terms such
as “attack” used in the questionnaire.
This questionnaire included questions concerning
daytime symptoms, limitation of activities, and noc-
turnal symptomsawaking during the 4 weeks prior
to the survey; this information is required for the defi-
nition of asthma control under the GINA 2006 guide-
lines. Subjects were also asked about their use of
peak-flow meters (PEFMs), most recent PEFM read-
ing, and smoking status. Furthermore, subjects were
asked a series of questions to evaluate their fre-
quency of asthma attacks (classified as few attacks,
seasonal attacks, and persistent attacks) during the
year prior to the survey. Five ACT-J questions were
also included in the questionnaire. Physicians were
asked to monitor the subjects’ completion of the
questionnaire and to supply details on their current
treatment, medication used for primary control, and
the type of asthma (atopic or non-atopic) as indicated
by the total serum IgE level or the detection of
allergen-specific IgE and the overall severity of dis-
ease.
Our survey definitions of GINA asthma control are
summarized in Table 1. The presence of daytime
symptoms was determined from our original survey
data, and the ACT-J questions were used to gauge the
limitations of activities and need for relieverrescue
treatment. The presence of nocturnal symptoms
awaking was derived from both our original survey
data and the ACT-J question. The decline in lung
function was determined from the PEFM value. Pa-
tients who reported few attacks during the last year
and no attacks during the 2 weeks prior to the survey
were judged to have no asthma exacerbation, while
patients reporting seasonal or persistent attacks with
no attacks during the 2 weeks prior to the survey
were considered to have had 1 or more exacerbations
in the last year. Patients who reported asthma attacks
during the 2 weeks prior to the survey were judged
as having had 1 or more exacerbations in the last 2
weeks. Based on these criteria, patients were classi-
fied as having controlled, partly controlled, or uncon-
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Table　1　The working defi nition of the GINA-defi ned asthma control used in this study
Levels of asthma control
Characteristic Controlled
(All of the following)
Partly controlled
(Any measure present
during the 4 weeks
prior to the survey)
Uncontrolled
Daytime symptoms† None (twice or less/week) More than twice/week Three or more 
features of partly 
controlled asthma 
present during any 
of the last 4 weeks
Limitations of activities‡ None Any
Nocturnal symptoms/awakening†,‡ None Any
Need for reliever/rescue treatment‡ None (twice or less/week) More than twice/week
Lung function (PEF)* Normal <80% predicted
Exacerbations§ None One or more
in the last year
One or more
in the last 2 weeks
GINA, Global Initiative for Asthma; PEFM, peak expiratory fl ow.
†Data derived from the survey questions.
‡Data derived from the asthma control test questions.
§“None” indicates the subject reported few attacks during the last year and no attacks during the 2 weeks prior to the survey. “One or 
more in the last year” indicates that the subject reported seasonal or persistent attacks during the last year and no attacks during the 2
weeks prior to the survey. “One or more in the last 2 weeks” indicates that the subject reported 1 or more attacks present during the 2 week
prior to the survey.
trolled asthma.
The analyses evaluated the relationship between
the ACT-J score and GINA-defined asthma control,
taking the GINA classification as the “true” classifica-
tion and the ACT-J score as the “predictor.” Our
analyses evaluated the relationships between the
ACT-J score and GINA-defined partly controlledun-
controlled versus controlled asthma and between the
ACT-J score and GINA-defined partly controlledcon-
trolled versus uncontrolled asthma. For the analysis,
receiver operating characteristic (ROC) curves (sen-
sitivity vs. [1 - specificity]) were plotted for the full
range of ACT-J score cut-off points. The Youden in-
dex, indicating the effectiveness of the ACT-J, was
calculated (The Youden index = sensitivity + specific-
ity - 1), and used in this study. This ranges between 0
and 1, with values close to 1 indicating that the effec-
tiveness is relatively large and value close to 0 indicat-
ing limited one. Sensitivity and specificity were used
to determine the area under the curve (AUC) values
with 95% confidence intervals (CI). The AUC summa-
rizes the relationship between the 2 measures by in-
corporating information from all ACT-J values. If the
ACT score was a perfect predictor, this area would
equal 1; if it were no better than random chance, it
would equal 0.5 (the straight line drawn on the ROC
curves). The performance levels of the ACT-J at dif-
ferent cut-off points were calculated and the ROC
curves drawn with the appropriate ranges of the 2
measures to make this relationship clear (Fig. 1A, B
and Table 4A, B). The kappa statistic, a means of
measuring agreement beyond that due to chance
alone between 2 sets of categorical observations and
is interpreted as follows: 0.81-1.00, almost perfect;
0.61-0.80, substantial; 0.41-0.60, moderate; 0.21-0.40,
fair; 0.00-0.20, slight; and <0, poor agreement30; was
also used for the optimal cut-off point of the ACT-J
score.
Representative results for all continuous variables
except the ACT scores were expressed as arithmetic
means with standard deviations. ACT scores were ex-
pressed as median values with interquartile ranges
(IQRs). Intergroup differences in continuous vari-
ables were evaluated using the Kruskal-Wallis test
and Mann-Whitney U test with the Bonferroni correc-
tion. A χ2 test with the Bonferroni correction was
used to assess the significance levels of differences in
proportions between groups. All statistical analyses
except the calculation of the AUC were performed
with the statistical software package StatView 5.0
PowerPC version (SAS Institute, Inc., Cary, NC,
USA), and the AUC was calculated using SPSS ver-
sion 17 (IBM SPSS Statistics, Inc., Chicago, IL, USA).




The study included patients from 24 large hospitals
(200 beds or more), 16 small hospitals (fewer than
200 beds), and 56 clinics (no beds). A total of 4,662
questionnaires were prepared, and 2,762 responses
were received (response rate: 59.2%). The rate of
PEFM use in this study was 23.7%, and we analyzed
data from the 419 patients with asthma who answered
the questionnaire and completed the 5 questions
from the ACT-J questionnaire and whose asthma con-
trol could be classified according to the GINA criteria
(Table 1). The patients’ characteristics, including the
number of cases, age, sex, duration of disease, type of
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Table　2　Characteristics of patients with controlled, partly controlled and uncontrolled asthma according to the GINA defi nitions
GINA classifi cation Controlled Partly controlled Uncontrolled
Number od cases 168 166 85
Age (years, mean ± SD) 62.5 ± 15.0 60.3 ± 16.6 56.5 ± 16.4*
Sex (%, male/female) 34.5/65.5 45.2/54.8 42.2/57.6
Duration (years, mean ± SD) 17.5 ± 14.7 17.7 ± 15.9 19.1 ± 17.6
Type (%, atopic/non-atopic) 70.8/25.6 68.7/26.5 67.0/24.7
Smoking status
non-smoker (%) 66.7 56.0 49.4*
ex-smoker (%) 20.8 34.9* 35.3*
current smoker (%) 11.3  9.0 15.3
Medication
rate of ICS use (%) 89.3 95.2 91.8
rate of OCS use (%)  4.8  4.8 11.8
rate of LABA use (%) 39.3 61.5*** 62.3**
rate of LTRA use (%) 49.9 60.2 64.7
rate of OSRT use (%) 32.5 46.4*** 49.9***
GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LTRA, leukotriene receptor antagonist; 
OCS, oral corticosteroid; OSRT, oral sustained-released theophylline.
*p < 0.05, **p < 0.01, ***p < 0.001 vs. controlled asthma.
Fig.　1A　Receiver operating characteristic curve for identify-
ing controlled asthma as defi ned by the 2006 Global Initiative 
for Asthma guidelines using the Asthma Control Test. 95%CI: 
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AUC = 0.76 (95%CI: 0.72-0.81)
Fig.　1B　Receiver operating characteristic curve for identi-
fying uncontrolled asthma as defi ned by the 2006 Global Ini-
tiative for Asthma guidelines using the Asthma Control Test. 
95%CI: 95% confi dence interval, °: cut-off points, arrow: cut-
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disease, smoking status and medication are summa-
rized by asthma control classification (controlled,
partly controlled, or uncontrolled asthma) in Table 2.
None of these characteristics differed significantly
among the 3 classifications except for the age of pa-
tients with uncontrolled asthma (p < 0.05). The pro-
portion of non-smokers was significantly lower (p <
0.05) among patients with uncontrolled asthma and
the proportions of ex-smokers significantly higher (p
< 0.05) among those with partly controlled and un-
controlled asthma than among those with controlled
asthma. The rates of LABA and OSRT use were sig-
ACT-J as a Predictor of GINA Control
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Table　3　Indicators of asthma control in patients with controlled, partly controlled and uncontrolled asthma according to the 
GINA defi nition
GINA classifi cation Controlled Partly controlled Uncontrolled
Frequency of asthma attacks in the year prior to the survey
Few attacks (%) 94.0 48.2*** 20***, #
Seasonal attacks (%)  0.0 44.6*** 37.6***
Persistent attacks (%)  0.0  1.8 30.6***, #
Not described  6.0  5.4 11.8
Asthma attacks in the 2 weeks prior to questionnaire
Attacks (%)  0.0  0.0 60.1***, ###
No attacks (%) 97.6 94.6 34.1***, ###
Not described (%)  1.2  5.4  5.8
%PEF (mean +/- SD) 101.2 ± 16.6 84.6 ± 27.6*** 76.4 ± 21.1***
ACT (median, [IQR]) 25 [24-25] 24 [23-25]*** 19 [17-21]***, ###
GINA, Global Initiative for Asthma; ACT, asthma control test; IQR, interquartile range; %PEF, peak expiratory fl ow as a percentage of the 
predicted peak-fl ow value.
***p < 0.001 v.s. controlled asthma, #p < 0.05, ###p < 0.001 vs. partly controlled asthma.
nificantly higher (p < 0.001 or p < 0.01) among pa-
tients with partly controlled and uncontrolled asthma
than among those with controlled asthma.
INDICATORS OF ASTHMA CONTROL
The indicators of asthma control are individually
summarized in Table 3. The proportions of patients
with few, seasonal, and persistent attacks during the
year prior to the survey in the controlled, partly con-
trolled, and uncontrolled asthma groups were 94.0,
0.0, and 0.0%; 48.2, 44.6, and 1.8%; and 20.0, 37.6, and
30.6%; respectively. The proportions of subjects with
few attacks were significantly lower (p < 0.001) in the
partially and uncontrolled asthma groups than in the
controlled asthma group, and the proportion with few
attacks was significantly lower (p < 0.05) in the un-
controlled asthma group than in the partially con-
trolled asthma group. The proportions of subjects
with seasonal attacks were significantly higher (p <
0.001) in the partly controlled and uncontrolled
asthma groups than in the controlled asthma group,
and the proportion with persistent attacks was signifi-
cantly higher in the uncontrolled asthma group than
in the controlled (p < 0.001) and partially controlled
(p < 0.05) asthma groups.
The proportions of subjects reporting attacks and
no attacks during the 2 weeks prior to the survey in
the controlled, partially controlled, and uncontrolled
asthma groups were 0.0 and 97.6%; 0.0 and 94.6%; and
60.1 and 34.1%; respectively. The proportions of those
reporting attacks and no attacks were significantly
higher and lower (p < 0.001), respectively, in the un-
controlled asthma group than in the controlled and
partially controlled asthma groups.
The peak expiratory flow (PEF) values as percent-
ages of the predicted PEF (%PEF, mean ± SD) in the
controlled, partly controlled, and uncontrolled
asthma groups were 101.2 ± 16.6, 84.6 ± 27.6, and
76.4 ± 21.1%, respectively. The %PEF values were sig-
nificantly lower (p < 0.001) in the partly controlled
and uncontrolled asthma groups than in the con-
trolled asthma group. The ACT-J scores (median
[IQR]) of the controlled, partly controlled, and uncon-
trolled asthma groups were 25 [24-25], 24 [23-25],
and 19 [17-21], respectively. The ACT-J scores were
significantly lower (p < 0.001) in the partly controlled
and uncontrolled asthma groups than in the con-
trolled asthma group, and the ACT-J score was sig-
nificantly lower (p < 0.001) in the uncontrolled
asthma group than in the partly controlled asthma
group.
ACCURACY OF ACT-J SCREENING DETERMI-
NATION OF THE OPTIMAL ACT CUT-OFF POINT
The performance of the ACT-J score for identifying
patients with controlled asthma is summarized in Ta-
ble 4A, which shows the performance levels of the
ACT-J score at different proposed cut-off points. A
cut-off point of <18 yielded poor ACT-J classification
accuracy and was therefore dismissed. An ACT cut-
off score of 23 produced the maximum value of the
Youden index (0.44); accordingly, we used an ACT
score of 23 as the optimal cut-off point for identifying
patients with controlled asthma. As shown on the
ROC curve, a cut-off point of 23 represents the point
closest to the top-left corner (Fig. 1A), which yields
the lowest rates of false-positive and false-negative
screening results. The AUC value was 0.76 (95%CI:
0.72-0.81); this was calculated using not only the data
shown in Table 4A but also the full ranges of the 2
measures including the data in Table 4A. An ACT-J
score of 23 predicted GINA-defined controlled
asthma with 54.9% accuracy, while an ACT-J score of
22 predicted GINA-defined uncontrolledpartly con-
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Table　4A　Performance of the ACT-J score at different cut-off points for predicting the GINA category of asthma control (con-
trolled vs. partly controlled/uncontrolled) in all patients (n = 419)
Cut-off point % sensitivity % specifi city % positive predicitive value % negative predictive value Youden index
25  64.9 71.3 60.2  75.2 0.362
24  88.1 55.0 56.7  87.3 0.431
23  97.0 46.6 54.9  95.9 0.436
22 100.0 37.8 51.9 100.0 0.378
21 100.0 27.1 47.9 100.0 0.271
20 100.0 20.7 45.8 100.0 0.207
19 100.0 15.9 44.3 100.0 0.159
18 100.0 10.4 42.7 100.0 0.104
ACT-J, Asthma Control Test Japanese version; GINA, Global Initiative for Asthma.
Table　4B　Performance of the ACT-J at different cut-off points for predicting the GINA category of asthma control (uncontrolled 
vs. partly controlled/controlled) in all patients (n = 419)
Cut-off point % sensitivity % specifi city % positive predicitive Value % negative predictive Value Youden Index
16 24.7 99.7 95.5 83.9 0.244
17 29.4 99.7 96.2 84.7 0.291
18 45.9 99.7 97.5 87.9 0.456
19 54.1 98.2 88.5 89.4 0.523
20 64.7 96.1 80.9 91.5 0.608
21 78.8 91.6 70.5 94.4 0.704
22 89.4 86.2 62.3 97.0 0.756
23 92.9 76.3 50.0 97.7 0.693
24 96.5 53.3 34.5 98.3 0.498
ACT-J, Asthma Control Test Japanese version; GINA, Global Initiative for Asthma.
Table　5　Number and percentage of patients with each 
asthma control status among the patients with ACT-J scores 









Controlled 163 (54.9) 5 (4.1)
Partly controlled 125 (42.1) 41 (33.6)
Uncontrolled  9 (3.0) 76 (62.3)
ACT-J, Asthma Control Test Japanese version; GINA, Global
Initiative for Asthma.
trolled asthma with 95.9% accuracy. A cut-off point of
23 for controlled asthma yielded a kappa level of
agreement for the entire patient population of 0.39.
The performance of the ACT-J score for identifying
patients with uncontrolled asthma is summarized in
Table 4B. A cut-off point of <16 yielded poor ACT
classification accuracy and was therefore dismissed.
The Youden index reached a maximum of 0.76 with
an ACT score of 22, making this the optimal cut-off
point for identifying patients with uncontrolled
asthma. A cut-off point of 22 is also the point closest
to the top-left corner of the ROC curve (Fig. 1B). The
AUC value was 0.93 (95% CI: 0.90-0.97), which was
also calculated using the full ranges of the 2 meas-
ures. An ACT-J score of 22 predicted GINA-defined
uncontrolled asthma with 62.3% accuracy, while an
ACT-J score of 23 predicted GINA-defined con-
trolledpartially controlled asthma with 99.1% accu-
racy. The cut-off point of22 for uncontrolled asthma
produced a kappa level of agreement for the entire
patient population of 0.63. The rates of controlled,
partly controlled, and uncontrolled asthma among
subjects with ACT-J scores of23 were 54.9, 42.1, and
3.0%, respectively, while the rates of controlled, partly
controlled, and uncontrolled asthma among subjects
with ACT-J scores of22 were 4.1, 33.6, and 62.3%, re-
spectively (Table 5).
DISCUSSION
This study aimed to evaluate the ACT-J score as a
predictor of GINA 2006 guidelines-defined asthma
control in actual clinical practice; this was of interest
because the ACT-J evaluation of asthma control re-
quires no lung function tests and is suitable for use
by general physicians, who play an important role in
asthma management and whose use of lung function
testing is not high.3,9-11 To our knowledge, this study
was the first such evaluation of the ACT-J.
When the ACT-J score was used to identify con-
trolled asthma, we found that an ACT-J score of 22
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predicted partly controlled or uncontrolled asthma as
defined by the GINA criteria with 95.9% accuracy (Ta-
ble 5). The AUC, the single most-informative meas-
ure of the ability of the ACT-J score to predict GINA-
defined asthma status, was 0.76 (95% CI: 0.72-0.81)
for identification of controlled asthma using this cut-
off (Fig. 1). However, the AUC for identification of
controlled asthma was lower than previously found
for other disease categories.31-33 Moreover, an ACT-J
score of 23 predicted GINA-defined controlled
asthma with 54.9% accuracy (Table 5), and the kappa
statistic (0.39) suggested fair agreement when the
cut-off point of23 was used for identifying controlled
asthma. On the other hand, when the ACT-J score
was used to identify uncontrolled asthma, an ACT-J
score of 22 predicted GINA-defined uncontrolled
asthma with 62.3% accuracy (Table 5). The AUC for
identification of uncontrolled asthma was 0.93 (95%
CI: 0.90-0.97), which is higher than previously found
for other disease categories.31-33 The kappa statistic
(0.63) also indicated substantial agreement for the
identification of uncontrolled asthma when the cut-off
point of 22 was used. These indicate that the ACT-J
was useful for predicting the patient’s GINA-defined
asthma control status and was particularly useful for
confirming that a patient’s asthma was uncontrolled
according to the GINA classification. When the cut-
off point 23 in the ACT-J for predicting GINA-defined
controlled asthma is used, we should pay an attention
to the fact that there are some patients with some
partly controlled asthma and a few patients with un-
controlled asthma among subjects with ACT-J scores
of 23. The under-treatment may occur on such pa-
tients. To avoid this, we should manage the asthmatic
patients using other clinical information as well as the
ACT-J.
There are several explanations for the low value of
the kappa statistic for the use of the cut-off point of
23 to identify controlled asthma. One of these is sim-
ply that substantial numbers of patients with an ACT-
J score of 23 had GINA-defined partly controlled
asthma (42.1%) and a few had uncontrolled asthma
(3.0%). Some of the discrepancy could be explained
by the different criteria for the timing of exacerba-
tions between the ACT-J and the GINA definitions. Of
patients with GINA-defined partly controlled asthma
and an ACT-J score of 23, 25.6% failed to meet the
GINA definition of controlled asthma despite having
only seasonal attacks. The ACT-J lists more specific
symptoms than the GINA definition, as was pointed
out by Thomas et al..16 On the other hand, only a few
patients with ACT-J scores of 23 (10.3%) had GINA-
defined uncontrolled asthma, resulting in a substan-
tial kappa statistic when the cut-off point of 22 was
used to identify uncontrolled asthma.
Another important result of this study is that the
optimal cut-off point was higher than in previous stud-
ies that were performed outside Japan using non-
Japanese versions of the ACT rather than the ACT-
J.16-19 The cause of this difference is unknown. The
nature of asthma does not differ fundamentally
among races; however, as the ACT-J relies on self-
reported answers, this difference might stem from
differences in how the symptoms of asthma are per-
ceived and expressed. The intensity levels of dyspnea
symptoms as experienced by individuals with asthma
do not correlate well with their degrees of airway ob-
struction as determined by spirometry.34,35 While pa-
tients with stable asthma always experience dyspnea
after inhalation of a bronchoconstrictive agent, the
degree of dyspnea associated with any fixed decline
(e.g., 20%) in the forced expiratory volume in 1 sec-
ond during peak expiratory flow varies widely.36 So-
matosensory amplification has recently been intro-
duced as an explanation of the dissociation of subjec-
tive and objective symptoms in various diseases.37,38
Somatosensory amplification has been reported to
play an important role in patients with asthma.39 Fur-
ther investigation, e.g., of race-specific differences in
somatosensory amplification, might be required to
explain the different cut-off point of the ACT-J score.
This study has several limitations. First, there is
some possibility of patient selection bias; the enrolled
subjects were regular visitors at one of the participat-
ing institutes, meaning that patients with recent-onset
asthma might not have been included in this study.
Second, some patients with seasonal asthma might
not visit medical institutes during asymptomatic peri-
ods. Therefore, there was no evidence of the efficacy
of the ACT-J score in such patients. A third limitation
relates to our selection of the GINA 2006 asthma con-
trol classification as the gold standard assessment of
asthma control, as has previously been pointed out by
Nguyen et al..17 In truth, there is no real gold stan-
dard for measuring asthma control; the GINA classifi-
cation is described as a “working scheme based on
current opinion, which has not been validated.17”
In summary, this study showed that ACT scores of
23 and 22 are useful for identifying patients with
controlled and uncontrolled asthma, respectively, as
defined by the GINA 2006 guidelines. The AUC val-
ues of the ROC curves indicate that the latter is more
strongly predictive than the former. The reason for
the unusually high cut-off point of the ACT-J is un-
clear and warrants further investigation.
REFERENCES
1. Hasegawa T, Suzuki E, Muramatsu Y et al. Questionnaire-
based analysis of the current level of asthma control and
management in Niigata Prefecture, Japan: Changes from
1998 to 2000. Allergol Int 2004;53:145-51.
2. Hasegawa T, Suzuki E, Terada M et al. Improvement of
asthma management in actual practice consistent with
prevalence of anti-inflammatory agents. Based on ques-
tionnaire surveys in Niigata Prefecture, Japan from 1998
to 2002. Allergol Int 2005;54:555-63.
3. Hasegawa T, Koya T, Sakagami T et al. Asthma control
Hasegawa T et al.
330 Allergology International Vol 62, No3, 2013 www.jsaweb.jp
and management changes in Japan surveyed using ques-
tionnaire. Intern Med 2012;51:567-74.
4. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy
for asthma management and prevention: GINA executive
summary. Eur Respir J 2008;31:143-78.
5. Ohta K, Yamaguchi M, Akiyama K et al. Japanese guide-
line for adult asthma. Allergol Int 2011;60:115-45.
6. Fukutomi Y, Taniguchi M, Watanabe J et al. Time trend
in the prevalence of adult asthma in Japan: Findings from
population-based surveys in Fujieda city in 1985, 1999,
and 2006. Allergol Int 2011;60:443-8.
7. Long AA. The burden of asthma and improving patient
outcomes. Am J Manag Care 2011;17(Suppl 3):S75-81.
8. Sullivan PW, Ghushchyan VH, Slejko JF, Belozeroff V,
Globe DR, Lin SL. The burden of adult asthma in the
United States: Evidence from the Medical Expenditure
Panel Survey. J Allergy Clin Immunol 2011;127:363-9.
9. Doerschug KC, Peterson MW, Dayton CS, Kline JN.
Asthma guidelines: An assessment of physician under-
standing and practice. Am J Respir Crit Care Med 1999;
159:1735-41.
10. Moore PL. Practice management and chronic obstructive
pulmonary disease in primary care. Am J Med 2007;120:
S23-7.
11. Roberts NJ, Smith SF, Partridge MR. Why is spirometry
underused in the diagnosis of the breathless patient: A
qualitative study. BMC Pulm Med 2011;11:37.
12. Nathan RA, Sorkness CA, Kosinski M et al. Development
of the asthma control test: A survey for assessing asthma
control. J Allergy Clin Immunol 2004;113:59-65.
13. Schatz M, Sorkness CA, Li JT et al. Asthma Control Test:
Reliability, validity, and responsiveness in patients not
previously followed by asthma specialists. J Allergy Clin
Immunol 2006;117:549-56.
14. Schatz M, Mosen DM, Kosinski M et al. Validity of the
Asthma Control Test completed at home. Am J Manag
Care 2007;13:661-7.
15. Zhou X, Ding FM, Lin JT, Yin KS. Validity of asthma con-
trol test for asthma control assessment in Chinese pri-
mary care settings. Chest 2009;135:904-10.
16. Thomas M, Kay S, Pike J et al. The Asthma Control Test
(ACT) as a predictor of GINA guideline-defined asthma
control: Analysis of a multinational cross-sectional survey.
Prim Care Respir J 2009;18:41-9.
17. Nguyen VN, Chavannes N, Le LT, Price D. The Asthma
Control Test (ACT) as an alternative tool to Global Initia-
tive for Asthma (GINA) guideline criteria for assessing
asthma control in Vietnamese outpatients. Prim Care
Respir J 2012;21:85-9.
18. Benkheder A, Bouacha H, Nafti S et al. Control of asthma
in the Maghreb: Results of the AIRMAG study. Respir
Med 2009;103(Suppl 2):S12-20.
19. Korn S, Both J, Jung M, Hübner M, Taube C, Buhl R. Pro-
spective evaluation of current asthma control using ACQ
and ACT compared with GINA criteria. Ann Allergy
Asthma Immunol 2011;107:474-9.
20. Suzuki E, Hasegawa T, Koya T et al. Questionnaire-based
characterization of bronchial asthma in elderly. Analysis
in Niigata Prefecture, Japan. Allergol Int 2002;51:241-8.
21. Yoshimine F, Hasegawa T, Suzuki E et al. Contribution of
aspirin intolerant asthma to near fatal asthma based on
questionnaire surveys in Niigata Prefecture, Japan. Respi-
rology 2005;10:477-84.
22. Satoh H, Hasegawa T, Suzuki E et al. Gender differences
in susceptibility of asthma to active smoking. Question-
naire based analysis in the Niigata Prefecture, Japan. Al-
lergol Int 2005;54:401-10.
23. Suzuki K, Hasegawa T, Sakagami T et al. Analysis of peri-
menstrual asthma based on questionnaire surveys in Ja-
pan. Allergol Int 2007;56:249-55.
24. Koyanagi K, Koya T, Sasagawa M et al. An analysis of fac-
tors that exacerbate asthma: Based on a Japanese ques-
tionnaire. Allergol Int 2009;58:519-27.
25. Ota K, Hasegawa T, Koya T et al. Analysis of inhaled cor-
ticosteroid selection in patients with bronchial asthma us-
ing a questionnaire survey. Effects of age, gender, and
disease severity. Allergol Int 2009;58:365-71.
26. Youkou A, Hasegawa T, Suzuki K et al. Influence of obe-
sity on control in asthmatic Japanese patients defined by
the Japanese definition of obesity. Intern Med 2011;50:
1911-6.
27. Hasegawa T, Koya T, Sakagami T et al. Analysis of de-
pression in asthmatic patients using the Japanese version
of Patient Health Questionnaire-9. Allergol Int 2012;61:
475-87.
28. Furukawa T, Hasegawa T, Suzuki K et al. Influence of un-
derweight on asthma control. Allergol Int 2012;61:489-96.
29. Hasegawa T, Koya T, Sakagami T et al. Efficacy of using
the Japanese version of the Asthma Control Test for de-
terming the level of asthma control in clinical settings. Al-
lergol Int 2012;61:609-17.
30. Landis JR, Koch GG. The measurement of observer
agreement for categorical data. Biometrics 1977;33:159-
74.
31. Price DB, Tinkelman DG, Nordyke RJ, Isonaka S, Halbert
RJ. Scoring system and clinical application of COPD diag-
nostic questionnaires. Chest 2006;129:1531-9.
32. Wallenstein GV, Carranza-Rosenzweig J, Kosinski M,
Blaisdell-Gross B, Gajria K, Jhingran P. A psychometric
comparison of three patient-based measures of asthma
control. Curr Med Res Opin 2007;23:369-77.
33. Weintraub JM, Sparrow D, Weiss ST. Receiver operating
characteristics curve analysis of cutaneous skin test reac-
tions to predict hay fever and asthma symptoms in the
Normative Aging Study. Allergy 2001;56:243-6.
34. Teeter JG, Bleecker ER. Relationship between airway ob-
struction and respiratory symptoms in adult asthmatics.
Chest 1998;113:272-7.
35. Osborne ML, Vollmer WM, Pedula KL, Wilkins J, Buist
AS, O’Hollaren M. Lack of correlation of symptoms with
specialist-assessed long-term asthma severity. Chest 1999;
115:85-91.
36. Chetta A, Gerra G, Foresi A et al. Personality profiles and
breathlessness perception in outpatients with different
gradings of asthma. Am J Respir Crit Care Med 1998;157:
116-22.
37. Muramatsu K, Miyaoka H, Muramatsu Y et al. The ampli-
fication of somatic symptoms in upper respiratory tract in-
fections. Gen Hosp Psychiatry 2002;24:172-5.
38. Nakao M, Barsky AJ, Kumano H, Kuboki T. Relationship
between somatosensory amplification and alexithymia in
a Japanese psychosomatic clinic. Psychosomatics 2002;43:
55-60.
39. Lavietes MH, Ameh J, Cherniack NS. Dyspnea and symp-
tom amplification in asthma. Respiration 2008;75:158-62.
